Selected research
Market Outlook & Growth Opportunities
Global Major Depressive Disorder Drug Market Outlook and Growth Opportunities 2026
Market perspective
The global Major Depressive Disorder Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.
The North America market for Major Depressive Disorder Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Major Depressive Disorder Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Major Depressive Disorder Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
In China, the Major Depressive Disorder Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Major global companies in the Major Depressive Disorder Drug market include Eli Lilly and Company, GlaxoSmithKline Plc, Intra-Cellular Therapies, Inc., Hua Medicine Ltd., H. Lundbeck A/S, F. Hoffmann-La Roche Ltd., e-Therapeutics Plc, Cerecor Inc. and Bristol-Myers Squibb Company, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Major Depressive Disorder Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Major Depressive Disorder Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Major Depressive Disorder Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Major Depressive Disorder Drug market size, projected growth trends, production technologies, key applications, and end-use industries.
Major Depressive Disorder Drug Segment by Company
Eli Lilly and Company
GlaxoSmithKline Plc
Intra-Cellular Therapies, Inc.
Hua Medicine Ltd.
H. Lundbeck A/S
F. Hoffmann-La Roche Ltd.
e-Therapeutics Plc
Cerecor Inc.
Bristol-Myers Squibb Company
Major Depressive Disorder Drug Segment by Type
AV-101
AVP-786
Basimglurant
Aripiprazole
Brexpiprazole
Others
Major Depressive Disorder Drug Segment by Application
Research Center
Hospital
Clinic
Major Depressive Disorder Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Major Depressive Disorder Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Major Depressive Disorder Drug market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Major Depressive Disorder Drug significant trends, drivers, influence factors in global and regions.
6. To analyze Major Depressive Disorder Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Major Depressive Disorder Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Major Depressive Disorder Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Major Depressive Disorder Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Major Depressive Disorder Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Major Depressive Disorder Drug industry.
Chapter 3: Detailed analysis of Major Depressive Disorder Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Major Depressive Disorder Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Major Depressive Disorder Drug in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
More report detail
Tables and figures
List of Tables
Table 1. Major Depressive Disorder Drug Industry Trends
Table 2. Major Depressive Disorder Drug Industry Drivers
Table 3. Major Depressive Disorder Drug Industry Opportunities and Challenges
Table 4. Major Depressive Disorder Drug Industry Restraints
Table 5. Global Major Depressive Disorder Drug Revenue by Company (US$ Million) & (2021-2026)
Table 6. Global Major Depressive Disorder Drug Revenue Share by Company (2021-2026)
Table 7. Global Major Depressive Disorder Drug Sales Volume by Company (W Units) & (2021-2026)
Table 8. Global Major Depressive Disorder Drug Sales Volume Share by Company (2021-2026)
Table 9. Global Major Depressive Disorder Drug Average Price (US$/Unit) of Company (2021-2026)
Table 10. Global Major Depressive Disorder Drug Company Ranking, (2024-2026) & (USD Million)
Table 11. Global Major Depressive Disorder Drug Key Company Manufacturing Base & Headquarters
Table 12. Global Major Depressive Disorder Drug Company, Product Type & Application
Table 13. Global Major Depressive Disorder Drug Company Establishment Date
Table 14. Global Company Market Concentration Ratio (CR5 and HHI)
Table 15. Global Major Depressive Disorder Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025)
Table 16. Mergers & Acquisitions, Expansion
Table 17. Significant Companies of AV-101
Table 18. Significant Companies of AVP-786
Table 19. Significant Companies of Basimglurant
Table 20. Significant Companies of Aripiprazole
Table 21. Significant Companies of Brexpiprazole
Table 22. Significant Companies of Others
Table 23. Global Major Depressive Disorder Drug Sales Volume by Type 2021 VS 2025 VS 2032 (W Units)
Table 24. Global Major Depressive Disorder Drug Sales Volume by Type (2021-2026) & (W Units)
Table 25. Global Major Depressive Disorder Drug Sales Volume by Type (2027-2032) & (W Units)
Table 26. Global Major Depressive Disorder Drug Sales Volume Share by Type (2021-2026)
Table 27. Global Major Depressive Disorder Drug Sales Volume Share by Type (2027-2032)
Table 28. Global Major Depressive Disorder Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million)
Table 29. Global Major Depressive Disorder Drug Sales Value by Type (2021-2026) & (US$ Million)
Table 30. Global Major Depressive Disorder Drug Sales Value by Type (2027-2032) & (US$ Million)
Table 31. Global Major Depressive Disorder Drug Sales Value Share by Type (2021-2026)
Table 32. Global Major Depressive Disorder Drug Sales Value Share by Type (2027-2032)
Table 33. Significant Companies of Research Center
Table 34. Significant Companies of Hospital
Table 35. Significant Companies of Clinic
Table 36. Global Major Depressive Disorder Drug Sales Volume by Application 2021 VS 2025 VS 2032 (W Units)
Table 37. Global Major Depressive Disorder Drug Sales Volume by Application (2021-2026) & (W Units)
Table 38. Global Major Depressive Disorder Drug Sales Volume by Application (2027-2032) & (W Units)
Table 39. Global Major Depressive Disorder Drug Sales Volume Share by Application (2021-2026)
Table 40. Global Major Depressive Disorder Drug Sales Volume Share by Application (2027-2032)
Table 41. Global Major Depressive Disorder Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million)
Table 42. Global Major Depressive Disorder Drug Sales Value by Application (2021-2026) & (US$ Million)
Table 43. Global Major Depressive Disorder Drug Sales Value by Application (2027-2032) & (US$ Million)
Table 44. Global Major Depressive Disorder Drug Sales Value Share by Application (2021-2026)
Table 45. Global Major Depressive Disorder Drug Sales Value Share by Application (2027-2032)
Table 46. Global Major Depressive Disorder Drug Sales by Region: 2021 VS 2025 VS 2032 (W Units)
Table 47. Global Major Depressive Disorder Drug Sales by Region (2021-2026) & (W Units)
Table 48. Global Major Depressive Disorder Drug Sales Market Share by Region (2021-2026)
Table 49. Global Major Depressive Disorder Drug Sales by Region (2027-2032) & (W Units)
Table 50. Global Major Depressive Disorder Drug Sales Market Share by Region (2027-2032)
Table 51. Global Major Depressive Disorder Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million)
Table 52. Global Major Depressive Disorder Drug Sales Value by Region (2021-2026) & (US$ Million)
Table 53. Global Major Depressive Disorder Drug Sales Value Share by Region (2021-2026)
Table 54. Global Major Depressive Disorder Drug Sales Value by Region (2027-2032) & (US$ Million)
Table 55. Global Major Depressive Disorder Drug Sales Value Share by Region (2027-2032)
Table 56. Global Major Depressive Disorder Drug Market Average Price (US$/Unit) by Region (2021-2026)
Table 57. Global Major Depressive Disorder Drug Market Average Price (US$/Unit) by Region (2027-2032)
Table 58. Global Major Depressive Disorder Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units)
Table 59. Global Major Depressive Disorder Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 60. Global Major Depressive Disorder Drug Sales by Country (2021-2026) & (W Units)
Table 61. Global Major Depressive Disorder Drug Sales Market Share by Country (2021-2026)
Table 62. Global Major Depressive Disorder Drug Sales by Country (2027-2032) & (W Units)
Table 63. Global Major Depressive Disorder Drug Sales Market Share by Country (2027-2032)
Table 64. Global Major Depressive Disorder Drug Sales Value by Country (2021-2026) & (US$ Million)
Table 65. Global Major Depressive Disorder Drug Sales Value Market Share by Country (2021-2026)
Table 66. Global Major Depressive Disorder Drug Sales Value by Country (2027-2032) & (US$ Million)
Table 67. Global Major Depressive Disorder Drug Sales Value Market Share by Country (2027-2032)
Table 68. Eli Lilly and Company Company Information
Table 69. Eli Lilly and Company Business Overview
Table 70. Eli Lilly and Company Major Depressive Disorder Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 71. Eli Lilly and Company Major Depressive Disorder Drug Product Portfolio
Table 72. Eli Lilly and Company Recent Development
Table 73. GlaxoSmithKline Plc Company Information
Table 74. GlaxoSmithKline Plc Business Overview
Table 75. GlaxoSmithKline Plc Major Depressive Disorder Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 76. GlaxoSmithKline Plc Major Depressive Disorder Drug Product Portfolio
Table 77. GlaxoSmithKline Plc Recent Development
Table 78. Intra-Cellular Therapies, Inc. Company Information
Table 79. Intra-Cellular Therapies, Inc. Business Overview
Table 80. Intra-Cellular Therapies, Inc. Major Depressive Disorder Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 81. Intra-Cellular Therapies, Inc. Major Depressive Disorder Drug Product Portfolio
Table 82. Intra-Cellular Therapies, Inc. Recent Development
Table 83. Hua Medicine Ltd. Company Information
Table 84. Hua Medicine Ltd. Business Overview
Table 85. Hua Medicine Ltd. Major Depressive Disorder Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 86. Hua Medicine Ltd. Major Depressive Disorder Drug Product Portfolio
Table 87. Hua Medicine Ltd. Recent Development
Table 88. H. Lundbeck A/S Company Information
Table 89. H. Lundbeck A/S Business Overview
Table 90. H. Lundbeck A/S Major Depressive Disorder Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 91. H. Lundbeck A/S Major Depressive Disorder Drug Product Portfolio
Table 92. H. Lundbeck A/S Recent Development
Table 93. F. Hoffmann-La Roche Ltd. Company Information
Table 94. F. Hoffmann-La Roche Ltd. Business Overview
Table 95. F. Hoffmann-La Roche Ltd. Major Depressive Disorder Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 96. F. Hoffmann-La Roche Ltd. Major Depressive Disorder Drug Product Portfolio
Table 97. F. Hoffmann-La Roche Ltd. Recent Development
Table 98. e-Therapeutics Plc Company Information
Table 99. e-Therapeutics Plc Business Overview
Table 100. e-Therapeutics Plc Major Depressive Disorder Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 101. e-Therapeutics Plc Major Depressive Disorder Drug Product Portfolio
Table 102. e-Therapeutics Plc Recent Development
Table 103. Cerecor Inc. Company Information
Table 104. Cerecor Inc. Business Overview
Table 105. Cerecor Inc. Major Depressive Disorder Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 106. Cerecor Inc. Major Depressive Disorder Drug Product Portfolio
Table 107. Cerecor Inc. Recent Development
Table 108. Bristol-Myers Squibb Company Company Information
Table 109. Bristol-Myers Squibb Company Business Overview
Table 110. Bristol-Myers Squibb Company Major Depressive Disorder Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 111. Bristol-Myers Squibb Company Major Depressive Disorder Drug Product Portfolio
Table 112. Bristol-Myers Squibb Company Recent Development
Table 113. Key Raw Materials
Table 114. Raw Materials Key Suppliers
Table 115. Major Depressive Disorder Drug Distributors List
Table 116. Major Depressive Disorder Drug Customers List
Table 117. Research Programs/Design for This Report
Table 118. Authors List of This Report
Table 119. Secondary Sources
Table 120. Primary Sources
List of Figures
Figure 1. Major Depressive Disorder Drug Product Image
Figure 2. Global Major Depressive Disorder Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032
Figure 3. Global Major Depressive Disorder Drug Sales Value (2021-2032) & (US$ Million)
Figure 4. Global Major Depressive Disorder Drug Sales (2021-2032) & (W Units)
Figure 5. Global Major Depressive Disorder Drug Sales Average Price (US$/Unit) & (2021-2032)
Figure 6. Global Major Depressive Disorder Drug Company Revenue Ranking in 2025 (US$ Million)
Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million)
Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 9. AV-101 Image
Figure 10. AVP-786 Image
Figure 11. Basimglurant Image
Figure 12. Aripiprazole Image
Figure 13. Brexpiprazole Image
Figure 14. Others Image
Figure 15. Global Major Depressive Disorder Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (W Units)
Figure 16. Global Major Depressive Disorder Drug Sales Volume Share 2021 VS 2025 VS 2032
Figure 17. Global Major Depressive Disorder Drug Sales Volume Share by Type (2021-2032)
Figure 18. Global Major Depressive Disorder Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million)
Figure 19. Global Major Depressive Disorder Drug Sales Value Share 2021 VS 2025 VS 2032
Figure 20. Global Major Depressive Disorder Drug Sales Value Share by Type (2021-2032)
Figure 21. Research Center Image
Figure 22. Hospital Image
Figure 23. Clinic Image
Figure 24. Global Major Depressive Disorder Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (W Units)
Figure 25. Global Major Depressive Disorder Drug Sales Volume Share 2021 VS 2025 VS 2032
Figure 26. Global Major Depressive Disorder Drug Sales Volume Share by Application (2021-2032)
Figure 27. Global Major Depressive Disorder Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million)
Figure 28. Global Major Depressive Disorder Drug Sales Value Share 2021 VS 2025 VS 2032
Figure 29. Global Major Depressive Disorder Drug Sales Value Share by Application (2021-2032)
Figure 30. Global Major Depressive Disorder Drug Sales by Region: 2021 VS 2025 VS 2032 (W Units)
Figure 31. Global Major Depressive Disorder Drug Sales Market Share by Region: 2021 VS 2025 VS 2032
Figure 32. Global Major Depressive Disorder Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million)
Figure 33. Global Major Depressive Disorder Drug Sales Value Share by Region: 2021 VS 2025 VS 2032
Figure 34. North America Major Depressive Disorder Drug Sales Value (2021-2032) & (US$ Million)
Figure 35. North America Major Depressive Disorder Drug Sales Value Share by Country (%), 2025 VS 2032
Figure 36. Europe Major Depressive Disorder Drug Sales Value (2021-2032) & (US$ Million)
Figure 37. Europe Major Depressive Disorder Drug Sales Value Share by Country (%), 2025 VS 2032
Figure 38. Asia-Pacific Major Depressive Disorder Drug Sales Value (2021-2032) & (US$ Million)
Figure 39. Asia-Pacific Major Depressive Disorder Drug Sales Value Share by Country (%), 2025 VS 2032
Figure 40. South America Major Depressive Disorder Drug Sales Value (2021-2032) & (US$ Million)
Figure 41. South America Major Depressive Disorder Drug Sales Value Share by Country (%), 2025 VS 2032
Figure 42. Middle East & Africa Major Depressive Disorder Drug Sales Value (2021-2032) & (US$ Million)
Figure 43. Middle East & Africa Major Depressive Disorder Drug Sales Value Share by Country (%), 2025 VS 2032
Figure 44. USA Major Depressive Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 45. USA Major Depressive Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 46. USA Major Depressive Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 47. Canada Major Depressive Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 48. Canada Major Depressive Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 49. Canada Major Depressive Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 50. Mexico Major Depressive Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 51. Mexico Major Depressive Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 52. Mexico Major Depressive Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 53. Germany Major Depressive Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 54. Germany Major Depressive Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 55. Germany Major Depressive Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 56. France Major Depressive Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 57. France Major Depressive Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 58. France Major Depressive Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 59. U.K. Major Depressive Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 60. U.K. Major Depressive Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 61. U.K. Major Depressive Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 62. Italy Major Depressive Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 63. Italy Major Depressive Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 64. Italy Major Depressive Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 65. Spain Major Depressive Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 66. Spain Major Depressive Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 67. Spain Major Depressive Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 68. Russia Major Depressive Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 69. Russia Major Depressive Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 70. Russia Major Depressive Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 71. Netherlands Major Depressive Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 72. Netherlands Major Depressive Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 73. Netherlands Major Depressive Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 74. Nordic Countries Major Depressive Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 75. Nordic Countries Major Depressive Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 76. Nordic Countries Major Depressive Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 77. China Major Depressive Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 78. China Major Depressive Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 79. China Major Depressive Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 80. Japan Major Depressive Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 81. Japan Major Depressive Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 82. Japan Major Depressive Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 83. South Korea Major Depressive Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 84. South Korea Major Depressive Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 85. South Korea Major Depressive Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 86. India Major Depressive Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 87. India Major Depressive Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 88. India Major Depressive Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 89. Australia Major Depressive Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 90. Australia Major Depressive Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 91. Australia Major Depressive Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 92. Southeast Asia Major Depressive Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 93. Southeast Asia Major Depressive Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 94. Southeast Asia Major Depressive Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 95. Brazil Major Depressive Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 96. Brazil Major Depressive Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 97. Brazil Major Depressive Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 98. Argentina Major Depressive Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 99. Argentina Major Depressive Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 100. Argentina Major Depressive Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 101. Chile Major Depressive Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 102. Chile Major Depressive Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 103. Chile Major Depressive Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 104. Colombia Major Depressive Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 105. Colombia Major Depressive Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 106. Colombia Major Depressive Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 107. Peru Major Depressive Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 108. Peru Major Depressive Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 109. Peru Major Depressive Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 110. Saudi Arabia Major Depressive Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 111. Saudi Arabia Major Depressive Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 112. Saudi Arabia Major Depressive Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 113. Israel Major Depressive Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 114. Israel Arabia Major Depressive Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 115. Israel Arabia Major Depressive Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 116. UAE Major Depressive Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 117. UAE Major Depressive Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 118. UAE Major Depressive Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 119. Turkey Major Depressive Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 120. Turkey Major Depressive Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 121. Turkey Major Depressive Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 122. Iran Major Depressive Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 123. Iran Major Depressive Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 124. Iran Major Depressive Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 125. Egypt Major Depressive Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 126. Egypt Major Depressive Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 127. Egypt Major Depressive Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 128. Major Depressive Disorder Drug Value Chain
Figure 129. Manufacturing Cost Structure
Figure 130. Major Depressive Disorder Drug Sales Mode & Process
Figure 131. Direct Comparison with Distribution Share
Figure 132. Distributors Profiles
Figure 133. Years Considered
Figure 134. Research Process
Figure 135. Key Executives Interviewed
Scope & coverage.
Types
- AV-101
- AVP-786
- Basimglurant
- Aripiprazole
- Brexpiprazole
- Others
Applications
- Research Center
- Hospital
- Clinic
Companies covered
- Eli Lilly and Company
- GlaxoSmithKline Plc
- Intra-Cellular Therapies, Inc.
- Hua Medicine Ltd.
- H. Lundbeck A/S
- F. Hoffmann-La Roche Ltd.
- e-Therapeutics Plc
- Cerecor Inc.
- Bristol-Myers Squibb Company
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Major Depressive Disorder Drug Sales Value (2021-2032)
- 1.2.2 Global Major Depressive Disorder Drug Sales Volume (2021-2032)
- 1.2.3 Global Major Depressive Disorder Drug Sales Average Price (2021-2032)
- 1.3 Assumptions and Limitations
- 1.4 Study Goals and Objectives
2 Major Depressive Disorder Drug Market Dynamics
- 2.1 Major Depressive Disorder Drug Industry Trends
- 2.2 Major Depressive Disorder Drug Industry Drivers
- 2.3 Major Depressive Disorder Drug Industry Opportunities and Challenges
- 2.4 Major Depressive Disorder Drug Industry Restraints
3 Major Depressive Disorder Drug Market by Company
- 3.1 Global Major Depressive Disorder Drug Company Revenue Ranking in 2025
- 3.2 Global Major Depressive Disorder Drug Revenue by Company (2021-2026)
- 3.3 Global Major Depressive Disorder Drug Sales Volume by Company (2021-2026)
- 3.4 Global Major Depressive Disorder Drug Average Price by Company (2021-2026)
- 3.5 Global Major Depressive Disorder Drug Company Ranking (2024-2026)
- 3.6 Global Major Depressive Disorder Drug Company Manufacturing Base and Headquarters
- 3.7 Global Major Depressive Disorder Drug Company Product Type and Application
- 3.8 Global Major Depressive Disorder Drug Company Establishment Date
- 3.9 Market Competitive Analysis
- 3.9.1 Global Major Depressive Disorder Drug Market Concentration Ratio (CR5 and HHI)
- 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
- 3.9.3 2025 Major Depressive Disorder Drug Tier 1, Tier 2, and Tier 3 Companies
- 3.10 Mergers and Acquisitions Expansion
4 Major Depressive Disorder Drug Market by Type
- 4.1 Major Depressive Disorder Drug Type Introduction
- 4.1.1 AV-101
- 4.1.2 AVP-786
- 4.1.3 Basimglurant
- 4.1.4 Aripiprazole
- 4.1.5 Brexpiprazole
- 4.1.6 Others
- 4.2 Global Major Depressive Disorder Drug Sales Volume by Type
- 4.2.1 Global Major Depressive Disorder Drug Sales Volume by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Major Depressive Disorder Drug Sales Volume by Type (2021-2032)
- 4.2.3 Global Major Depressive Disorder Drug Sales Volume Share by Type (2021-2032)
- 4.3 Global Major Depressive Disorder Drug Sales Value by Type
- 4.3.1 Global Major Depressive Disorder Drug Sales Value by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Major Depressive Disorder Drug Sales Value by Type (2021-2032)
- 4.3.3 Global Major Depressive Disorder Drug Sales Value Share by Type (2021-2032)
5 Major Depressive Disorder Drug Market by Application
- 5.1 Major Depressive Disorder Drug Application Introduction
- 5.1.1 Research Center
- 5.1.2 Hospital
- 5.1.3 Clinic
- 5.2 Global Major Depressive Disorder Drug Sales Volume by Application
- 5.2.1 Global Major Depressive Disorder Drug Sales Volume by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Major Depressive Disorder Drug Sales Volume by Application (2021-2032)
- 5.2.3 Global Major Depressive Disorder Drug Sales Volume Share by Application (2021-2032)
- 5.3 Global Major Depressive Disorder Drug Sales Value by Application
- 5.3.1 Global Major Depressive Disorder Drug Sales Value by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Major Depressive Disorder Drug Sales Value by Application (2021-2032)
- 5.3.3 Global Major Depressive Disorder Drug Sales Value Share by Application (2021-2032)
6 Major Depressive Disorder Drug Regional Sales and Value Analysis
- 6.1 Global Major Depressive Disorder Drug Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Major Depressive Disorder Drug Sales by Region (2021-2032)
- 6.2.1 Global Major Depressive Disorder Drug Sales by Region: 2021-2026
- 6.2.2 Global Major Depressive Disorder Drug Sales by Region (2027-2032)
- 6.3 Global Major Depressive Disorder Drug Sales Value by Region: 2021 VS 2025 VS 2032
- 6.4 Global Major Depressive Disorder Drug Sales Value by Region (2021-2032)
- 6.4.1 Global Major Depressive Disorder Drug Sales Value by Region: 2021-2026
- 6.4.2 Global Major Depressive Disorder Drug Sales Value by Region (2027-2032)
- 6.5 Global Major Depressive Disorder Drug Market Price Analysis by Region (2021-2026)
- 6.6 North America
- 6.6.1 North America Major Depressive Disorder Drug Sales Value (2021-2032)
- 6.6.2 North America Major Depressive Disorder Drug Sales Value Share by Country, 2025 VS 2032
- 6.7 Europe
- 6.7.1 Europe Major Depressive Disorder Drug Sales Value (2021-2032)
- 6.7.2 Europe Major Depressive Disorder Drug Sales Value Share by Country, 2025 VS 2032
- 6.8 Asia-Pacific
- 6.8.1 Asia-Pacific Major Depressive Disorder Drug Sales Value (2021-2032)
- 6.8.2 Asia-Pacific Major Depressive Disorder Drug Sales Value Share by Country, 2025 VS 2032
- 6.9 South America
- 6.9.1 South America Major Depressive Disorder Drug Sales Value (2021-2032)
- 6.9.2 South America Major Depressive Disorder Drug Sales Value Share by Country, 2025 VS 2032
- 6.10 Middle East & Africa
- 6.10.1 Middle East & Africa Major Depressive Disorder Drug Sales Value (2021-2032)
- 6.10.2 Middle East & Africa Major Depressive Disorder Drug Sales Value Share by Country, 2025 VS 2032
7 Major Depressive Disorder Drug Country-level Sales and Value Analysis
- 7.1 Global Major Depressive Disorder Drug Sales by Country: 2021 VS 2025 VS 2032
- 7.2 Global Major Depressive Disorder Drug Sales Value by Country: 2021 VS 2025 VS 2032
- 7.3 Global Major Depressive Disorder Drug Sales by Country (2021-2032)
- 7.3.1 Global Major Depressive Disorder Drug Sales by Country (2021-2026)
- 7.3.2 Global Major Depressive Disorder Drug Sales by Country (2027-2032)
- 7.4 Global Major Depressive Disorder Drug Sales Value by Country (2021-2032)
- 7.4.1 Global Major Depressive Disorder Drug Sales Value by Country (2021-2026)
- 7.4.2 Global Major Depressive Disorder Drug Sales Value by Country (2027-2032)
- 7.5 USA
- 7.5.1 USA Major Depressive Disorder Drug Sales Value Growth Rate (2021-2032)
- 7.5.2 USA Major Depressive Disorder Drug Sales Value Share by Type, 2025 VS 2032
- 7.5.3 USA Major Depressive Disorder Drug Sales Value Share by Application, 2025 VS 2032
- 7.6 Canada
- 7.6.1 Canada Major Depressive Disorder Drug Sales Value Growth Rate (2021-2032)
- 7.6.2 Canada Major Depressive Disorder Drug Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Canada Major Depressive Disorder Drug Sales Value Share by Application, 2025 VS 2032
- 7.7 Mexico
- 7.6.1 Mexico Major Depressive Disorder Drug Sales Value Growth Rate (2021-2032)
- 7.6.2 Mexico Major Depressive Disorder Drug Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Mexico Major Depressive Disorder Drug Sales Value Share by Application, 2025 VS 2032
- 7.8 Germany
- 7.8.1 Germany Major Depressive Disorder Drug Sales Value Growth Rate (2021-2032)
- 7.8.2 Germany Major Depressive Disorder Drug Sales Value Share by Type, 2025 VS 2032
- 7.8.3 Germany Major Depressive Disorder Drug Sales Value Share by Application, 2025 VS 2032
- 7.9 France
- 7.9.1 France Major Depressive Disorder Drug Sales Value Growth Rate (2021-2032)
- 7.9.2 France Major Depressive Disorder Drug Sales Value Share by Type, 2025 VS 2032
- 7.9.3 France Major Depressive Disorder Drug Sales Value Share by Application, 2025 VS 2032
- 7.10 U.K.
- 7.10.1 U.K. Major Depressive Disorder Drug Sales Value Growth Rate (2021-2032)
- 7.10.2 U.K. Major Depressive Disorder Drug Sales Value Share by Type, 2025 VS 2032
- 7.10.3 U.K. Major Depressive Disorder Drug Sales Value Share by Application, 2025 VS 2032
- 7.11 Italy
- 7.11.1 Italy Major Depressive Disorder Drug Sales Value Growth Rate (2021-2032)
- 7.11.2 Italy Major Depressive Disorder Drug Sales Value Share by Type, 2025 VS 2032
- 7.11.3 Italy Major Depressive Disorder Drug Sales Value Share by Application, 2025 VS 2032
- 7.12 Spain
- 7.12.1 Spain Major Depressive Disorder Drug Sales Value Growth Rate (2021-2032)
- 7.12.2 Spain Major Depressive Disorder Drug Sales Value Share by Type, 2025 VS 2032
- 7.12.3 Spain Major Depressive Disorder Drug Sales Value Share by Application, 2025 VS 2032
- 7.13 Russia
- 7.13.1 Russia Major Depressive Disorder Drug Sales Value Growth Rate (2021-2032)
- 7.13.2 Russia Major Depressive Disorder Drug Sales Value Share by Type, 2025 VS 2032
- 7.13.3 Russia Major Depressive Disorder Drug Sales Value Share by Application, 2025 VS 2032
- 7.14 Netherlands
- 7.14.1 Netherlands Major Depressive Disorder Drug Sales Value Growth Rate (2021-2032)
- 7.14.2 Netherlands Major Depressive Disorder Drug Sales Value Share by Type, 2025 VS 2032
- 7.14.3 Netherlands Major Depressive Disorder Drug Sales Value Share by Application, 2025 VS 2032
- 7.15 Nordic Countries
- 7.15.1 Nordic Countries Major Depressive Disorder Drug Sales Value Growth Rate (2021-2032)
- 7.15.2 Nordic Countries Major Depressive Disorder Drug Sales Value Share by Type, 2025 VS 2032
- 7.15.3 Nordic Countries Major Depressive Disorder Drug Sales Value Share by Application, 2025 VS 2032
- 7.16 China
- 7.16.1 China Major Depressive Disorder Drug Sales Value Growth Rate (2021-2032)
- 7.16.2 China Major Depressive Disorder Drug Sales Value Share by Type, 2025 VS 2032
- 7.16.3 China Major Depressive Disorder Drug Sales Value Share by Application, 2025 VS 2032
- 7.17 Japan
- 7.17.1 Japan Major Depressive Disorder Drug Sales Value Growth Rate (2021-2032)
- 7.17.2 Japan Major Depressive Disorder Drug Sales Value Share by Type, 2025 VS 2032
- 7.17.3 Japan Major Depressive Disorder Drug Sales Value Share by Application, 2025 VS 2032
- 7.18 South Korea
- 7.18.1 South Korea Major Depressive Disorder Drug Sales Value Growth Rate (2021-2032)
- 7.18.2 South Korea Major Depressive Disorder Drug Sales Value Share by Type, 2025 VS 2032
- 7.18.3 South Korea Major Depressive Disorder Drug Sales Value Share by Application, 2025 VS 2032
- 7.19 India
- 7.19.1 India Major Depressive Disorder Drug Sales Value Growth Rate (2021-2032)
- 7.19.2 India Major Depressive Disorder Drug Sales Value Share by Type, 2025 VS 2032
- 7.19.3 India Major Depressive Disorder Drug Sales Value Share by Application, 2025 VS 2032
- 7.20 Australia
- 7.20.1 Australia Major Depressive Disorder Drug Sales Value Growth Rate (2021-2032)
- 7.20.2 Australia Major Depressive Disorder Drug Sales Value Share by Type, 2025 VS 2032
- 7.20.3 Australia Major Depressive Disorder Drug Sales Value Share by Application, 2025 VS 2032
- 7.21 Southeast Asia
- 7.21.1 Southeast Asia Major Depressive Disorder Drug Sales Value Growth Rate (2021-2032)
- 7.21.2 Southeast Asia Major Depressive Disorder Drug Sales Value Share by Type, 2025 VS 2032
- 7.21.3 Southeast Asia Major Depressive Disorder Drug Sales Value Share by Application, 2025 VS 2032
- 7.22 Brazil
- 7.22.1 Brazil Major Depressive Disorder Drug Sales Value Growth Rate (2021-2032)
- 7.22.2 Brazil Major Depressive Disorder Drug Sales Value Share by Type, 2025 VS 2032
- 7.22.3 Brazil Major Depressive Disorder Drug Sales Value Share by Application, 2025 VS 2032
- 7.23 Argentina
- 7.23.1 Argentina Major Depressive Disorder Drug Sales Value Growth Rate (2021-2032)
- 7.23.2 Argentina Major Depressive Disorder Drug Sales Value Share by Type, 2025 VS 2032
- 7.23.3 Argentina Major Depressive Disorder Drug Sales Value Share by Application, 2025 VS 2032
- 7.24 Chile
- 7.24.1 Chile Major Depressive Disorder Drug Sales Value Growth Rate (2021-2032)
- 7.24.2 Chile Major Depressive Disorder Drug Sales Value Share by Type, 2025 VS 2032
- 7.24.3 Chile Major Depressive Disorder Drug Sales Value Share by Application, 2025 VS 2032
- 7.25 Colombia
- 7.25.1 Colombia Major Depressive Disorder Drug Sales Value Growth Rate (2021-2032)
- 7.25.2 Colombia Major Depressive Disorder Drug Sales Value Share by Type, 2025 VS 2032
- 7.25.3 Colombia Major Depressive Disorder Drug Sales Value Share by Application, 2025 VS 2032
- 7.26 Peru
- 7.26.1 Peru Major Depressive Disorder Drug Sales Value Growth Rate (2021-2032)
- 7.26.2 Peru Major Depressive Disorder Drug Sales Value Share by Type, 2025 VS 2032
- 7.26.3 Peru Major Depressive Disorder Drug Sales Value Share by Application, 2025 VS 2032
- 7.27 Saudi Arabia
- 7.27.1 Saudi Arabia Major Depressive Disorder Drug Sales Value Growth Rate (2021-2032)
- 7.27.2 Saudi Arabia Major Depressive Disorder Drug Sales Value Share by Type, 2025 VS 2032
- 7.27.3 Saudi Arabia Major Depressive Disorder Drug Sales Value Share by Application, 2025 VS 2032
- 7.28 Israel
- 7.28.1 Israel Major Depressive Disorder Drug Sales Value Growth Rate (2021-2032)
- 7.28.2 Israel Major Depressive Disorder Drug Sales Value Share by Type, 2025 VS 2032
- 7.28.3 Israel Major Depressive Disorder Drug Sales Value Share by Application, 2025 VS 2032
- 7.29 UAE
- 7.29.1 UAE Major Depressive Disorder Drug Sales Value Growth Rate (2021-2032)
- 7.29.2 UAE Major Depressive Disorder Drug Sales Value Share by Type, 2025 VS 2032
- 7.29.3 UAE Major Depressive Disorder Drug Sales Value Share by Application, 2025 VS 2032
- 7.30 Turkey
- 7.30.1 Turkey Major Depressive Disorder Drug Sales Value Growth Rate (2021-2032)
- 7.30.2 Turkey Major Depressive Disorder Drug Sales Value Share by Type, 2025 VS 2032
- 7.30.3 Turkey Major Depressive Disorder Drug Sales Value Share by Application, 2025 VS 2032
- 7.31 Iran
- 7.31.1 Iran Major Depressive Disorder Drug Sales Value Growth Rate (2021-2032)
- 7.31.2 Iran Major Depressive Disorder Drug Sales Value Share by Type, 2025 VS 2032
- 7.31.3 Iran Major Depressive Disorder Drug Sales Value Share by Application, 2025 VS 2032
- 7.32 Egypt
- 7.32.1 Egypt Major Depressive Disorder Drug Sales Value Growth Rate (2021-2032)
- 7.32.2 Egypt Major Depressive Disorder Drug Sales Value Share by Type, 2025 VS 2032
- 7.32.3 Egypt Major Depressive Disorder Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
- 8.1 Eli Lilly and Company
- 8.1.1 Eli Lilly and Company Company Information
- 8.1.2 Eli Lilly and Company Business Overview
- 8.1.3 Eli Lilly and Company Major Depressive Disorder Drug Sales, Value and Gross Margin (2021-2026)
- 8.1.4 Eli Lilly and Company Major Depressive Disorder Drug Product Portfolio
- 8.1.5 Eli Lilly and Company Recent Developments
- 8.2 GlaxoSmithKline Plc
- 8.2.1 GlaxoSmithKline Plc Company Information
- 8.2.2 GlaxoSmithKline Plc Business Overview
- 8.2.3 GlaxoSmithKline Plc Major Depressive Disorder Drug Sales, Value and Gross Margin (2021-2026)
- 8.2.4 GlaxoSmithKline Plc Major Depressive Disorder Drug Product Portfolio
- 8.2.5 GlaxoSmithKline Plc Recent Developments
- 8.3 Intra-Cellular Therapies, Inc.
- 8.3.1 Intra-Cellular Therapies, Inc. Company Information
- 8.3.2 Intra-Cellular Therapies, Inc. Business Overview
- 8.3.3 Intra-Cellular Therapies, Inc. Major Depressive Disorder Drug Sales, Value and Gross Margin (2021-2026)
- 8.3.4 Intra-Cellular Therapies, Inc. Major Depressive Disorder Drug Product Portfolio
- 8.3.5 Intra-Cellular Therapies, Inc. Recent Developments
- 8.4 Hua Medicine Ltd.
- 8.4.1 Hua Medicine Ltd. Company Information
- 8.4.2 Hua Medicine Ltd. Business Overview
- 8.4.3 Hua Medicine Ltd. Major Depressive Disorder Drug Sales, Value and Gross Margin (2021-2026)
- 8.4.4 Hua Medicine Ltd. Major Depressive Disorder Drug Product Portfolio
- 8.4.5 Hua Medicine Ltd. Recent Developments
- 8.5 H. Lundbeck A/S
- 8.5.1 H. Lundbeck A/S Company Information
- 8.5.2 H. Lundbeck A/S Business Overview
- 8.5.3 H. Lundbeck A/S Major Depressive Disorder Drug Sales, Value and Gross Margin (2021-2026)
- 8.5.4 H. Lundbeck A/S Major Depressive Disorder Drug Product Portfolio
- 8.5.5 H. Lundbeck A/S Recent Developments
- 8.6 F. Hoffmann-La Roche Ltd.
- 8.6.1 F. Hoffmann-La Roche Ltd. Company Information
- 8.6.2 F. Hoffmann-La Roche Ltd. Business Overview
- 8.6.3 F. Hoffmann-La Roche Ltd. Major Depressive Disorder Drug Sales, Value and Gross Margin (2021-2026)
- 8.6.4 F. Hoffmann-La Roche Ltd. Major Depressive Disorder Drug Product Portfolio
- 8.6.5 F. Hoffmann-La Roche Ltd. Recent Developments
- 8.7 e-Therapeutics Plc
- 8.7.1 e-Therapeutics Plc Company Information
- 8.7.2 e-Therapeutics Plc Business Overview
- 8.7.3 e-Therapeutics Plc Major Depressive Disorder Drug Sales, Value and Gross Margin (2021-2026)
- 8.7.4 e-Therapeutics Plc Major Depressive Disorder Drug Product Portfolio
- 8.7.5 e-Therapeutics Plc Recent Developments
- 8.8 Cerecor Inc.
- 8.8.1 Cerecor Inc. Company Information
- 8.8.2 Cerecor Inc. Business Overview
- 8.8.3 Cerecor Inc. Major Depressive Disorder Drug Sales, Value and Gross Margin (2021-2026)
- 8.8.4 Cerecor Inc. Major Depressive Disorder Drug Product Portfolio
- 8.8.5 Cerecor Inc. Recent Developments
- 8.9 Bristol-Myers Squibb Company
- 8.9.1 Bristol-Myers Squibb Company Company Information
- 8.9.2 Bristol-Myers Squibb Company Business Overview
- 8.9.3 Bristol-Myers Squibb Company Major Depressive Disorder Drug Sales, Value and Gross Margin (2021-2026)
- 8.9.4 Bristol-Myers Squibb Company Major Depressive Disorder Drug Product Portfolio
- 8.9.5 Bristol-Myers Squibb Company Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Major Depressive Disorder Drug Value Chain Analysis
- 9.1.1 Major Depressive Disorder Drug Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Major Depressive Disorder Drug Sales Mode & Process
- 9.2 Major Depressive Disorder Drug Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Major Depressive Disorder Drug Distributors
- 9.2.3 Major Depressive Disorder Drug Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
$4,250USD
Buy nowPDF by email within 3–5 working days after payment confirmation.
Talk to an analyst